TY - JOUR
T1 - Impaired angiogenesis and extracellular matrix metabolism in autosomal-dominant hyper-IgE syndrome
AU - Dmitrieva, Natalia I.
AU - Walts, Avram D.
AU - Nguyen, Dai Phuong
AU - Grubb, Alex
AU - Zhang, Xue
AU - Wang, Xujing
AU - Ping, Xianfeng
AU - Jin, Hui
AU - Yu, Zhen
AU - Yu, Zu Xi
AU - Yang, Dan
AU - Schwartzbeck, Robin
AU - Dalgard, Clifton L.
AU - Kozel, Beth A.
AU - Levin, Mark D.
AU - Knutsen, Russell H.
AU - Liu, Delong
AU - Milner, Joshua D.
AU - López, Diego B.
AU - O’Connell, Michael P.
AU - Lee, Chyi Chia Richard
AU - Myles, Ian A.
AU - Hsu, Amy P.
AU - Freeman, Alexandra F.
AU - Holland, Steven M.
AU - Chen, Guibin
AU - Boehm, Manfred
N1 - Publisher Copyright:
Copyright: © 2020, American Society for Clinical Investigation.
PY - 2020/8/3
Y1 - 2020/8/3
N2 - There are more than 7000 described rare diseases, most lacking specific treatment. Autosomal-dominant hyper-IgE syndrome (AD-HIES, also known as Job’s syndrome) is caused by mutations in STAT3. These patients present with immunodeficiency accompanied by severe nonimmunological features, including skeletal, connective tissue, and vascular abnormalities, poor postinfection lung healing, and subsequent pulmonary failure. No specific therapies are available for these abnormalities. Here, we investigated underlying mechanisms in order to identify therapeutic targets. Histological analysis of skin wounds demonstrated delayed granulation tissue formation and vascularization during skin-wound healing in AD-HIES patients. Global gene expression analysis in AD-HIES patient skin fibroblasts identified deficiencies in a STAT3-controlled transcriptional network regulating extracellular matrix (ECM) remodeling and angiogenesis, with hypoxia-inducible factor 1α (HIF-1α) being a major contributor. Consistent with this, histological analysis of skin wounds and coronary arteries from AD-HIES patients showed decreased HIF-1α expression and revealed abnormal organization of the ECM and altered formation of the coronary vasa vasorum. Disease modeling using cell culture and mouse models of angiogenesis and wound healing confirmed these predicted deficiencies and demonstrated therapeutic benefit of HIF-1α–stabilizing drugs. The study provides mechanistic insights into AD-HIES pathophysiology and suggests potential treatment options for this rare disease.
AB - There are more than 7000 described rare diseases, most lacking specific treatment. Autosomal-dominant hyper-IgE syndrome (AD-HIES, also known as Job’s syndrome) is caused by mutations in STAT3. These patients present with immunodeficiency accompanied by severe nonimmunological features, including skeletal, connective tissue, and vascular abnormalities, poor postinfection lung healing, and subsequent pulmonary failure. No specific therapies are available for these abnormalities. Here, we investigated underlying mechanisms in order to identify therapeutic targets. Histological analysis of skin wounds demonstrated delayed granulation tissue formation and vascularization during skin-wound healing in AD-HIES patients. Global gene expression analysis in AD-HIES patient skin fibroblasts identified deficiencies in a STAT3-controlled transcriptional network regulating extracellular matrix (ECM) remodeling and angiogenesis, with hypoxia-inducible factor 1α (HIF-1α) being a major contributor. Consistent with this, histological analysis of skin wounds and coronary arteries from AD-HIES patients showed decreased HIF-1α expression and revealed abnormal organization of the ECM and altered formation of the coronary vasa vasorum. Disease modeling using cell culture and mouse models of angiogenesis and wound healing confirmed these predicted deficiencies and demonstrated therapeutic benefit of HIF-1α–stabilizing drugs. The study provides mechanistic insights into AD-HIES pathophysiology and suggests potential treatment options for this rare disease.
UR - http://www.scopus.com/inward/record.url?scp=85089052693&partnerID=8YFLogxK
U2 - 10.1172/JCI135490
DO - 10.1172/JCI135490
M3 - Article
C2 - 32369445
AN - SCOPUS:85089052693
SN - 0021-9738
VL - 140
SP - 4167
EP - 4181
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 8
ER -